Monoclonal Antibody Diagnostic Reagents Market 2026 Investment Analysis To Obtain The Exact Specification On Future Growth

Press Release

Antibodies are common and essential research tools for various applications, including enzyme-linked immunosorbant assay (ELISA), flow cytometric analysis, immunoprecipitation, immunocytochemistry, immunohistochemistry, and western blotting. Monoclonal antibodies (MAbs) are important diagnostic reagents used in biomedical research, microbiological research, in diagnosis of chlamydia, hepatitis, herpes simplex, HIV, and influenza infections, and also for the treatment of diseases such as cancer.

Get Exclusive Sample Report at:

Diagnostic tests based on the use of MAbs as reagents are routinely used in enzyme-linked immunosorbent assays and radioimmunoassay in laboratories. These tests measure the circulating concentrations of hormones (gastrin, growth hormone, human chorionic gonadotropin, insulin, progesterone, thyroid stimulating hormone, thyroxine, triiodothyronine, and renin) and cell products (blood clotting factors, blood group antigens, histocompatibility antigens, interferon, interleukins, and tumor markers).

Monoclonal Antibody Diagnostic Reagents Market Dynamics

Increasing use of monoclonal antibodies in various R&D applications, cancer therapies, and immunological disorders is expected to drive growth of the global monoclonal antibody diagnostic reagents market size. Monoclonal  antibody  diagnostic  kits  are  increasingly  used  to  detect  communicable  diseases  including  transfusion  transmissible  infections (TTI). According to World Health Organization (WHO) data of 2017, each year about 15 million people die due to infectious diseases in emerging economies. Tropical parasitic infections such as schitosomiasi and sexually transmitted infections such as syphilis also cause morbidity. There is an urgent need for development of accurate, simple, and stable diagnostic tools.

Non-infectious diseases are the leading cause of mortality and morbidity worldwide. As per the WHO 2017 data, around 40 million individuals suffering from cardiovascular diseases, cancer, chronic respiratory diseases, diabetes, and stroke die every year across the globe. Prevailing cancer incidence rate are expected to fuel demand for disease diagnosis. According to International Agency for Research on Cancer (IARC), the incidence of cancer is expected to reach to 26.8 million new cases and 17.1 million deaths annually by the year 2030.

Monoclonal Antibody Diagnostic Reagents Market Regional Insights

Regional segmentation of monoclonal antibody diagnostic reagents market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant in the global monoclonal antibody diagnostic reagents market in 2026 in terms of revenue share, owing to the presence of well-established healthcare infrastructure and increasing government funding for cancer research and technology for development of new diagnostics procedures. In 2016, National Cancer Institute (NCI) received a total funding of $4.952.6 billion, reflecting an increase of five percent, or $262.1 million from 2015. The number of monoclonal antibody products approved for commercial sale in the U.S. and Europe has grown steadily for the last several years.

Download PDF Brochure Of This Research Report @

Monoclonal Antibody Diagnostic Reagents Market Competitive Landscape

Key players operating in the monoclonal antibody diagnostic reagents market include AnaSpec, BioGenex, Bio-Rad, Biocare Medical, BioVision, Celltrion, Creative Diagnostics, GenWay Biotech, Innovent Biologics, Medix Biochemica, Qiagen, and Teva Pharmaceutical Ltd.